The drug pricing landscape is undergoing unprecedented change. Policy initiatives, from the Inflation Reduction Act’s Medicare Drug Price Negotiation Program and inflation rebates to emerging Most Favored Nation (MFN) frameworks like the GENEROUS, GLOBE, and GUARD models, are rapidly reshaping market access. Combined with shifting 340B regulations, reimbursement updates, trade policies, and global reference pricing, healthcare stakeholders face complex decisions around pricing strategy, portfolio investment, and product commercialization.

Watch this on-demand discussion featuring experts from CMS and ADVI Health as they examine the downstream impacts of these initiatives on patient access, pharmaceutical spending, and long-term innovation.

Speakers

  • Lindsay Bealor Greenleaf, SVP of Market Access & Policy Strategy, ADVI Health
  • Alicia Silver, VP of Emerging Therapies, ADVI Health
  • Brenna Raines, VP of Market Access & Policy Strategy, ADVI Health

Ready to Navigate Drug Pricing Changes for Your Portfolio?

Policy updates like Medicare price negotiations and MFN frameworks require proactive commercial strategies. Reach out to the ADVI Health team to discuss how these shifting policy dynamics impact your specific product or pipeline.

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.

Start now.